Strictly speaking mixed airway inflammation is a respiratory disease and can be categorized as tracheitis or bronchitis. The occurrence of mixed airway inflammation is mainly considered to be related to the co-infection of multiple pathogens, such as bacteria, viruses, mycoplasma, etc. The inflammation caused by these pathogens is mainly confined to the mucosa of the trachea and bronchi, and the irritation of the mucosa of the trachea and bronchi can lead to congestion and swelling of the mucosa, and an increase in the amount of secretion, resulting in clinical symptoms such as coughing, coughing up sputum, shortness of breath, asthma, or chest tightness. In addition, the stimulation of the immune system by inflammation can also cause fever, during which the patient will have a loss of appetite, fear of cold, fatigue, dizziness, headache and other clinical symptoms. For the treatment of mixed airway inflammation, broad-spectrum antibiotics such as ceftriaxone sodium and macrolides such as azithromycin should be used to treat the cause of the inflammation based on the diagnosis of the type of pathogen causing the inflammation; if the mixed airway inflammation is not effectively controlled, the inflammation can go down to the lungs and cause lung infection. This disease is highly specialized, should be timely to regular hospitals, under the guidance of the doctor to determine the specific treatment plan, and actively cooperate with the treatment, to avoid deterioration of the condition.